- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
14 result(s) found for: Trisomy 18.
Displaying page 1 of 1.
EudraCT Number: 2010-021134-66 | Sponsor Protocol Number: IJL-AFHT-TH10 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Institut Jerome Lejeune | ||||||||||||||||||
Full Title: Efficacy assessment of systematic treatment with folinic acid and thyroid hormone on psychomotor development of Down Syndrome young children | ||||||||||||||||||
Medical condition: Down syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-008342-20 | Sponsor Protocol Number: RAA08-015 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit). | |||||||||||||
Medical condition: Down's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001263-23 | Sponsor Protocol Number: BP27832 | Start Date*: 2014-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) | |||||||||||||
Medical condition: Down Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000309-75 | Sponsor Protocol Number: | Start Date*: 2005-08-26 |
Sponsor Name:Christian Geisler, Rigshospitalet, dept. Haematology 4042 | ||
Full Title: HOVON 68 CLL: A randomized phase III study in prevously untreated patients with biological high risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab. | ||
Medical condition: Chronic lymphocytic leukaemia (CLL) in biological high-risk group: Unmutated and/or with deletion 17p and/or deletion 11q and/or trisomy 12. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Ongoing) SE (Ongoing) FI (Completed) BE (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001936-45 | Sponsor Protocol Number: matab4 | Start Date*: 2011-05-25 |
Sponsor Name: | ||
Full Title: Pertussis vaccination in pregnancy | ||
Medical condition: The number of reported pertussis cases is rising, also in very young infants. Different strategies are possible to close the gap of susceptibility between the loss of maternal antibodies and prote... | ||
Disease: | ||
Population Age: In utero, Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001476-22 | Sponsor Protocol Number: 04-30 | Start Date*: 2016-02-16 | |||||||||||
Sponsor Name:Onconova Therapeutics, Inc. | |||||||||||||
Full Title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent | |||||||||||||
Medical condition: Myelodysplastic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HR (Completed) PL (Prematurely Ended) SE (Completed) BE (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004824-19 | Sponsor Protocol Number: ML21206 | Start Date*: 2008-08-08 |
Sponsor Name:Roche Austria GmbH | ||
Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | ||
Medical condition: Chronic Lymphocytic Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001279-39 | Sponsor Protocol Number: CA180-083 | Start Date*: 2006-09-15 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant... | ||
Medical condition: Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-004946-27 | Sponsor Protocol Number: E2020-A001-219 | Start Date*: 2017-05-18 |
Sponsor Name:Eisai Inc. | ||
Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D... | ||
Medical condition: Down Syndrome, Cognitive Dysfunction | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-013651-29 | Sponsor Protocol Number: AGMT_CLL8/A | Start Date*: 2010-01-13 | |||||||||||
Sponsor Name:AGMT | |||||||||||||
Full Title: MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004949-92 | Sponsor Protocol Number: E2020-A001-336 | Start Date*: 2017-03-09 |
Sponsor Name:Eisai Inc. | ||
Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with... | ||
Medical condition: Down Syndrome, Cognitive Dysfunction | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-004948-11 | Sponsor Protocol Number: E2020-A001-335 | Start Date*: 2017-03-09 |
Sponsor Name:Eisai Inc. | ||
Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D... | ||
Medical condition: Down Syndrome, Cognitive Dysfunction | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001573-89 | Sponsor Protocol Number: D8220C00008 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) FI (Ongoing) ES (Ongoing) FR (Ongoing) DK (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002714-23 | Sponsor Protocol Number: LLC1114 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.